Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer-Reference-Cited by-同舟云学术

Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer

Published:2018-10-16 Issue:3 Volume:14 Page:48-54
ISSN:1999-8627
Container-title:Tumors of female reproductive system
language:
Short-container-title:Tumors of female reproductive system

Author:

Slonimskaya E. M.¹^ORCID,Doroshenko A. V.¹^ORCID,Kazantseva P. V.¹^ORCID,Tarabanovskaya N. A.¹^ORCID,Vernadsky R. Yu.¹

Affiliation:

1. Oncology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Abstract

Adjuvant hormone therapy is considered the gold standard of therapy for hormone receptor-positive operable breast cancer. The approach to adjuvant hormone therapy in premenopausal patients has changed significantly in recent years. This change was caused by clinical trials, which have confirmed the advantage of adding ovarian suppression to tamoxifen or aromatase inhibitors monotherapy. Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in premenopausal patients with breast cancer should be based on the assessment of risks for relapse, expected effectiveness of treatment and evaluation of drug safety.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynaecology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference25 articles.

1. Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi M.: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii Minzdrava Rossii», 2017. [Malignant tumors in Russia in 2015 (incidence and mortality). Eds.: A. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Moscow: P. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Radiology Center, Ministry of Health of Russia, 2017. (In Russ.)].

2. SEER Cancer Statistics Review, 1975–2014. N. Howlader, A.M. Noone, M. Krapcho, D. Miller , K. Bishop, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J.Feuer, K.A. Cronin (eds). Bethesda, MD: National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.

3. Lambertini M., Pinto A.C., Ameye L. et al. The prognostic performance of adjuvant! Online and Nottingham prognostic index in young breast cancer patients. Br J Cancer 2016;115:1471–8.

4. Partridge A.H., Hughes M.E., Warner E.T. et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol 2016;34:3308–14.

5. Senkus E., Kyriakides S., Penault-Llorca F. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi7–vi23.